Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cross screening panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
Adrenergic alpha2C Eurofins Panlabs panel
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Assay data:195 Active, 66 Activity ≤ 1 µM, 1241 Tested
Inhibition of alpha2C adrenergic receptor (unknown origin) upto 10000 nM
Displacement of [3H]-RX 821002 from rat alpha2 adrenoceptor at 10 uM after 60 mins by scintillation counting analysis relative to control
Assay data:3 Tested
Agonist activity at human adrenergic receptor expressed in CHO cells
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
Agonist activity at human adrenergic receptor expressed in CHO cells assessed as intrinsic activity
Assay data:2 Tested
Displacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysis
Antagonist activity at alpha2c-adrenoceptor (unknown origin) assessed as reduction in adrenaline-induced response by measuring equilibrium binding constant
Assay data:12 Active, 11 Activity ≤ 1 nM, 12 Activity ≤ 1 µM, 12 Tested
Inhibition of alpha2C adrenergic receptor (unknown origin) at 10 uM
Binding affinity to adrenergic alpha 2c receptor (unknown origin)
Assay data:1 Active, 1 Tested
In Vitro Radioligand Binding Assay from US Patent US20240000767: "COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA"
Assay data:126 Active, 20 Activity ≤ 1 nM, 118 Activity ≤ 1 µM, 126 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Binding affinity to alpha2C AR (unknown origin) assessed as inhibition constant
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Selectivity interaction (Enzyme panel (GPCRS, ion channels, and transporters)) EUB0000194b ADRA2C
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000548a ADRA2C
Selectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2C
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on